Overview of CRISPR
CRISPR is an innovative instrument that is changing lives and creating significant impact in the field of medicine. CRISPR, which stands for “Clustered Regularly Interspaced Short Palindromic Repeats,” is present in prokaryotes—tiny, unicellular organisms lacking organelles. These sequences are situated within the genomes of prokaryotes, which organize a cell’s DNA into clusters.
As a gene editing instrument, CRISPR is utilized to alter specific segments of DNA to address serious illnesses. It is especially advantageous as it aids in protecting the body from viral threats by integrating the invading DNA into its own genome, which enables it to identify and eliminate the virus in subsequent encounters. Notably, in comparison to other gene editing techniques, CRISPR is significantly more accurate and simpler to program, facilitating an easier process of sequence reconstruction. While traditional gene-editing tools generally depend on a single protein, CRISPR employs RNA-guided targeting alongside the Cas9 enzyme.
Mechanism of CRISPR
CRISPR operates by leveraging a natural defense process found in bacteria, enabling them to detect and eliminate viral threats. When a virus invades a bacterial cell (a prokaryote), the bacterium retains a piece of the invader’s DNA within its own genome as a genetic “memory.” This capacity allows the bacterium to recognize and react more efficiently to subsequent infections.
In gene editing, this system is modified using two crucial elements: the Cas9 enzyme, which acts as molecular scissors to cleave DNA, and guide RNA, which directs Cas9 to the intended genetic sequence for modification. Once the targeted DNA is severed, the cell’s inherent repair mechanisms engage, granting researchers the opportunity to introduce alterations to the genetic material.
In contrast to earlier tools that depended on difficult-to-reprogram proteins, CRISPR’s RNA-guided approach is more adaptable, straightforward to design, and exceptionally accurate. This ease and precision have made CRISPR applicable in various fields, including medicine, agriculture, production, and microbiology—such as modifying microbes to enhance yield. However, as explored in this article, the expanding capabilities raise substantial ethical issues, particularly around germline editing and genetic enhancement.
First Patient to Receive a Personalized CRISPR Treatment
In February 2025, the first personalized CRISPR treatment in the world was administered to a baby named KJ to address a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme crucial for converting ammonia (produced during protein metabolism) into urea. A research team led by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia formulated this treatment after years of exploration in gene editing and cooperation with other specialists.
Their research concentrated on disorders impacting the urea cycle, leading to hazardous ammonia accumulation, which can harm organs such as the brain and liver. They customized the treatment specifically for KJ’s type of CPS1 deficiency through preclinical studies on analogous variants.
Up until now, the only CRISPR treatments sanctioned by the U.S. FDA have been for more prevalent diseases like sickle cell disease and beta thalassemia, which affect thousands to hundreds of thousands of individuals. In KJ’s situation, his treatment was developed within six months following his birth, aimed at his unique CPS1 variant. The team devised a base editing therapy that was delivered through lipid nanoparticles to his liver to rectify the dysfunctional enzyme.
The February treatment was the initial dose of three; KJ received the subsequent two in March and April 2025. As of his final dose, he has not experienced any significant side effects, demonstrates improved tolerance to dietary protein, and requires less medication to control ammonia levels. Although ongoing monitoring will be necessary, Ahrens-Nicklas indicates that the outcomes thus far are encouraging.
Ethical Implications of CRISPR
Like any revolutionary technology, CRIS